Shi Yuankai
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Int J Hematol. 2018 Apr;107(4):405-412. doi: 10.1007/s12185-018-2404-8. Epub 2018 Jan 31.
Lymphoma is a large group of lymphoid hematopoietic malignancies including Hodgkin lymphoma and non-Hodgkin's lymphoma. The various subtypes of lymphoma are different in clinical features, response to treatment and prognoses. The relative frequency of specific subtypes of lymphoma varies geographically. The mature T cell lymphoma is much more common in East Asia compared with Western countries. Chemotherapy plays an important role in the treatment of lymphoma. With advances in understanding the biology and genetics of lymphoma, many new agents are used in the treatment of lymphoma. In mainland China, some new agents and new combination chemotherapy regimens showed high efficacy and good tolerability. Chidamide, a histone deacetylase inhibitor, has been approved for the treatment of relapsed or refractory peripheral T cell lymphoma by the China Food and Drug Administration. Anti-programmed death 1 antibodies and chimeric antigen receptor-engineered T cells have been explored for lymphoma immunotherapy in Chinese patients. Advances in the treatment have substantially increased the likelihood of cure for patients with lymphoma.
淋巴瘤是一大类淋巴造血系统恶性肿瘤，包括霍奇金淋巴瘤和非霍奇金淋巴瘤。淋巴瘤的各种亚型在临床特征、对治疗的反应和预后方面存在差异。淋巴瘤特定亚型的相对发病率在地理上有所不同。与西方国家相比，成熟T细胞淋巴瘤在东亚更为常见。化疗在淋巴瘤的治疗中起着重要作用。随着对淋巴瘤生物学和遗传学认识的进展，许多新药物被用于淋巴瘤的治疗。在中国大陆，一些新药物和新的联合化疗方案显示出高效和良好的耐受性。西达本胺，一种组蛋白去乙酰化酶抑制剂，已被中国食品药品监督管理总局批准用于治疗复发或难治性外周T细胞淋巴瘤。抗程序性死亡1抗体和嵌合抗原受体工程化T细胞已在中国患者中用于淋巴瘤免疫治疗的探索。治疗方面的进展显著提高了淋巴瘤患者治愈的可能性。
